Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$227.62 USD
+9.38 (4.30%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $222.99 -4.63 (-2.03%) 4:50 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Charles River Laboratories International, Inc. [CRL]
Reports for Purchase
Showing records 381 - 386 ( 386 total )
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Positive Read from Covance Early Development Strength
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Soft 1Q14 to Put Charles River in Catch-Up Mode for Rest of 2014
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
We are initiating coverage with a HOLD rating with the stock trading at ~11.4x our 2015 EBITDA estimate of ~$317 million (consensus: $311 million)
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Initiation of Coverage of Biopharmaceutical Services
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D